Neurobiology of Aging
Volume 28, Issue 4 , Pages 507-514 , April 2007

CSF Aβ42, Tau and phosphorylated Tau, APOE ɛ4 allele and MCI type in progressive MCI

  • Sanna-Kaisa Herukka

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 17 163213; fax: +358 17 162048.
    • ,
  • Seppo Helisalmi

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • ,
  • Merja Hallikainen

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • ,
  • Susanna Tervo

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • ,
  • Hilkka Soininen

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland
    • ,
  • Tuula Pirttilä

      Affiliations

    • Department of Neuroscience and Neurology, Brain Research Unit, Clinical Research Center, Mediteknia, University of Kuopio, 70211 Kuopio, Finland
    • Department of Neurology, Kuopio University Hospital, 70211 Kuopio, Finland

Received 23 June 2005 ,Revised 20 December 2005 ,Accepted 9 February 2006.

References 

  1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders. 4th ed.. Washington: APA; 1994;
  2. Amieva H, Letenneur L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D’Alchee-Biree F, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord. 2004;18:87–93
  3. Andreasen N, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Cerebrospinal fluid levels of total-Tau, phospho-Tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol Scand. 2003;179(Suppl):47–51
  4. Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology. 2005;64:834–841
  5. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. Neuropsychologia. 1967;5:135–140
  6. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in non-demented elderly patients with memory loss. Arch Neurol. 2001;58:411–416
  7. Butters N, Granholm E, Salmon DP, Grant I, Wolfe J. Episodic and semantic memory: a comparison of amnesic and demented patients. J Clin Exp Neuropsychol. 1987;9:479–497
  8. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid Tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?. Arch Neurol. 2003;60:1696–1702
  9. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923
  10. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol. 1999;58:376–388
  11. DeCarli C, Mungas D, Harvey D, Reed B, Weiner M, Chui H, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology. 2004;63:220–227
  12. Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the framingham cohort. Arch Neurol. 2000;57:808–813
  13. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, et al. Prospective belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatr. 2003;74:1148–1151
  14. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278:1349–1356
  15. Flicker C, Ferris SH, Reisberg B. Mild cognitive impairment in the elderly: predictors of dementia. Neurology. 1991;41:1006–1009
  16. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  17. Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, et al. High cerebrospinal fluid Tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol. 1998;55:937–945
  18. Ganguli M, Dodge HH, Shen C, DeKosky ST. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology. 2004;63:115–121
  19. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Alzheimer's Disease Cooperative Study Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  20. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid(1–42) and Tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatr. 2004;9(7):705–710
  21. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and Tau or phosphorylated Tau and prediction of progressive mild cognitive impairment. Neurology. 2005;64:1294–1297
  22. Hsiung GY, Sadovnick AD, Feldman H. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the canadian study of health and aging. CMAJ. 2004;171:863–867
  23. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1–42) and Tau levels in CSF. Neurology. 1999;52:1555–1562
  24. Jack CR, Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52:1397–1403
  25. Kaplan EF, Goodglass H, Weintraub S. The boston naming test. Boston: Kaplan and Goodglass; 1991;
  26. Kawas CH, Corrada MM, Brookmeyer R, Morrison A, Resnick SM, Zonderman AB, et al. Visual memory predicts Alzheimer's disease more than a decade before diagnosis. Neurology. 2003;60:1089–1093
  27. Killiany RJ, Hyman BT, Gomez-Isla T, Moss MB, Kikinis R, Jolesz F, et al. MRI measures of entorhinal cortex versus hippocampus in preclinical AD. Neurology. 2002;58:1188–1196
  28. Lehtimaki T, Moilanen T, Viikari J, Akerblom HK, Ehnholm C, Ronnemaa T, et al. Apolipoprotein E phenotypes in finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 1990;31:487–495
  29. Luis CA, Barker WW, Loewenstein DA, Crum TA, Rogaeva E, Kawarai T, et al. Conversion to dementia among two groups with cognitive impairment. A preliminary report. Dement Geriatr Cogn Disord. 2004;18:307–313
  30. Maruyama M, Matsui T, Tanji H, Nemoto M, Tomita N, Ootsuki M, et al. Cerebrospinal fluid Tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways. Arch Neurol. 2004;61:716–720
  31. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology. 1984;34:939–944
  32. Meyer J, Xu G, Thornby J, Chowdhury M, Quach M. Longitudinal analysis of abnormal domains comprising mild cognitive impairment (MCI) during aging. J Neurol Sci. 2002;201:19–25
  33. Morris JC, Price AL. Pathologic correlates of non-demented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci. 2001;17:101–118
  34. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, et al. Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol. 2001;58:397–405
  35. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414
  36. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159–1165
  37. Neuropathology Group . Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. neuropathology group of the medical research council cognitive function and ageing study (MRC CFAS). Lancet. 2001;357:169–175
  38. Pennanen C, Kivipelto M, Tuomainen S, Hartikainen P, Hanninen T, Laakso MP, et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD. Neurobiol Aging. 2004;25:303–310
  39. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;
  40. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58:1985–1992
  41. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274–1278
  42. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology. 2004;62:2116–2118
  43. Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord. 2005;19:113–119
  44. Reitan RM. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–276
  45. Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A. Cerebrospinal fluid Tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol. 2002;59:1729–1734
  46. Royall DR, Palmer R, Chiodo LK, Polk MJ. Executive control mediates memory's association with change in instrumental activities of daily living: the freedom house study. J Am Geriatr Soc. 2005;53:11–17
  47. Royall DR, Chiodo LK, Polk MJ. Misclassification is likely in the assessment of mild cognitive impairment. Neuroepidemiology. 2004;23:185–191
  48. Russel EW. A multiple scoring method for the assessment of complex memory functions. J Cons Clin Psychol. 1975;43:800–809
  49. Saxton J, Lopez OL, Ratcliff G, Dulberg C, Fried LP, Carlson MC, et al. Preclinical Alzheimer disease: neuropsychological test performance 1.5–8 years prior to onset. Neurology. 2004;63:2341–2347
  50. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766
  51. Skoog I, Davidsson P, Aevarsson O, Vanderstichele H, Vanmechelen E, Blennow K. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord. 2003;15:169–176
  52. Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F, et al. Italian Longitudinal Study on Aging Working Group Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882–1891
  53. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:1977–1981
  54. Strozyk D, Blennow K, White LR, Launer LJ. CSF abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology. 2003;60:652–656
  55. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, et al. Cerebrospinal fluid beta-amyloid1-42 and Tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatr. 2004;56:670–676
  56. Tsukamoto K, Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, et al. Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med. 1993;121:598–602
  57. Wechsler D. Wechsler memory scale, revised manual. San Antonio: Psychological Corporation; 1987;
  58. Wechsler D. Wechsler adult intelligence scale, revised. Cleveland: Psychological Corporation; 1981;

PII: S0197-4580(06)00048-0

doi: 10.1016/j.neurobiolaging.2006.02.001

Neurobiology of Aging
Volume 28, Issue 4 , Pages 507-514 , April 2007

Article Tools

* Image Usage & Resolution